DURECT Corporation (DRRX): Price and Financial Metrics
DURECT Corporation (DRRX)
Today's Latest Price: $2.10 USD
Updated Jul 10 4:00pm
Add DRRX to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 213 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
DRRX Stock Summary
- With a one year PEG ratio of 589.49, Durect Corp is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 93.68% of US stocks.
- Price to trailing twelve month operating cash flow for DRRX is currently 105.63, higher than 97.21% of US stocks with positive operating cash flow.
- With a price/sales ratio of 14.59, Durect Corp has a higher such ratio than 90.76% of stocks in our set.
- Stocks that are quantitatively similar to DRRX, based on their financial statements, market capitalization, and price volatility, are TNAV, INFI, AKBA, ACIU, and ORMP.
- Visit DRRX's SEC page to see the company's official filings. To visit the company's web site, go to www.durect.com.
DRRX Stock Price Chart Technical Analysis Charts
DRRX Price/Volume Stats
| Current price | $2.10 | 52-week high | $3.95 |
| Prev. close | $2.17 | 52-week low | $0.64 |
| Day low | $2.02 | Volume | 1,033,096 |
| Day high | $2.18 | Avg. volume | 1,559,957 |
| 50-day MA | $2.34 | Dividend yield | N/A |
| 200-day MA | $2.06 | Market Cap | 411.65M |
DURECT Corporation (DRRX) Company Bio
DURECT Corporation, a specialty pharmaceutical company, focuses on the development of pharmaceuticals products based on its proprietary drug formulations and delivery platform technologies in the United States, Europe, Japan, and internationally. The company was founded in 1998 and is based in Cupertino, California.
DRRX Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $2.10 | $3.53 | 60% |
We started the process of determining a valid price forecast for Durect Corp with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Durect Corp ranked in the 58th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. In terms of the factors that were most noteworthy in this DCF analysis for DRRX, they are:
- The company has produced more trailing twelve month cash flow than merely 9.1% of its sector Healthcare.
- Durect Corp's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than only 0% of US stocks with positive free cash flow.
- Durect Corp's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -8.5. This coverage rate is greater than that of merely 9% of stocks we're observing for the purpose of forecasting via discounted cash flows.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | 57% |
| 1% | 58% |
| 2% | 60% |
| 3% | 61% |
| 4% | 63% |
| 5% | 65% |
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as DRRX, try UTHR, MEDP, HNGR, QDEL, and UNH.
Loading social stream, please wait...